A Phase 1 interventional study of Linagliptin/metformin and Metformin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-20.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To establish bioequivalence (BE) under fed conditions between metformin in linagliptin/metformin fixed dose combination tablet and metformin reference product administered in free combination togther with linagliptin
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
fixed dose combination tablet (FDC)
Drug: Linagliptin/metformin
single tablets
Drug: Metformin · Drug: Linagliptin
Drug pages: Linagliptin · Metformin
FDC
single tablet Metformin
single tablet Linagliptin
Area Under Curve From 0 to tz Hours (AUC0-tz) of Metformin
AUC0-tz represents the area under the concentration curve of metformin in plasma from 0 to the time of the last quantifiable plasma contentration of the analyte. Note, the geometric mean is actually an adjusted geometric mean.
Time frame: 0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours
Maximum Concentration (Cmax) of Metformin
Cmax represents the maximum concentration of metformin in plasma. Note, the geometric mean is actually an adjusted geometric mean.
Time frame: 0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours
Area Under Curve From 0 to Infinity Hours (AUC0-infty) of Metformin
AUC0-infty represents the area under the concentration curve of metformin in plasma from time 0 extrapolated to infinity. Note, the geometric mean is actually an adjusted geometric mean.
Time frame: 0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours
Time to Maximum Concentration (Tmax) of Metformin
Time from dosing to the maximum concentration of metformin in plasma.
Time frame: 0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours
Terminal Half-life t1/2 of Metformin
The terminal half-life of metformin in plasma is denoted by t1/2.
Time frame: 0:20, 0:40, 1, 1:30, 2, 3, 4, 5, 6, 8, 12, 24, 34, 48, 72 hours
| Milestone | Lina+Met Single Tablets / Lina+Met FDC Tablet | Lina+Met FDC Tablet / Lina+Met Single Tablets |
|---|---|---|
| Started | 16 | 16 |
| Completed | 16 | 16 |
| Not completed | 0 | 0 |
| Milestone | Lina+Met Single Tablets / Lina+Met FDC Tablet | Lina+Met FDC Tablet / Lina+Met Single Tablets |
|---|---|---|
| Started | 16 | 16 |
| Completed | 16 | 15 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Milestone | Lina+Met Single Tablets / Lina+Met FDC Tablet | Lina+Met FDC Tablet / Lina+Met Single Tablets |
|---|---|---|
| Started | 16 | 15 |
| Completed | 16 | 15 |
| Not completed | 0 | 0 |
AUC0-infty represents the area under the concentration curve of metformin in plasma from time 0 extrapolated to infinity. Note, the geometric mean is actually an adjusted geometric mean.
| ng·h/mL | Lina+Met Single Tablets | Lina+Met FDC Tablet |
|---|---|---|
| Area Under Curve From 0 to Infinity Hours (AUC0-infty) of Metformin | 7343.59 ± 9.7 | 7174.30 ± 9.7 |
Time from dosing to the maximum concentration of metformin in plasma.
| Hours | Lina+Met Single Tablets | Lina+Met FDC Tablet |
|---|---|---|
| Time to Maximum Concentration (Tmax) of Metformin | 4.00 (2.00 to 6.00) | 4.00 (1.00 to 6.00) |
The terminal half-life of metformin in plasma is denoted by t1/2.
| Hours | Lina+Met Single Tablets | Lina+Met FDC Tablet |
|---|---|---|
| Terminal Half-life t1/2 of Metformin | 9.14 ± 87.4 | 8.03 ± 86.0 |
AUC0-tz represents the area under the concentration curve of metformin in plasma from 0 to the time of the last quantifiable plasma contentration of the analyte. Note, the geometric mean is actually an adjusted geometric mean.
| ng·h/mL | Lina+Met Single Tablets | Lina+Met FDC Tablet |
|---|---|---|
| Area Under Curve From 0 to tz Hours (AUC0-tz) of Metformin | 7219.03 ± 9.8 | 7057.52 ± 9.8 |
Cmax represents the maximum concentration of metformin in plasma. Note, the geometric mean is actually an adjusted geometric mean.
| ng/mL | Lina+Met Single Tablets | Lina+Met FDC Tablet |
|---|---|---|
| Maximum Concentration (Cmax) of Metformin | 855.09 ± 10.0 | 844.72 ± 10.0 |
Collected over First treatment with study drug until End-of-Study (which was within 4 to 14 days after last study drug administration), i.e., 39 to 49 days after first treatment with study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lina+Met Single Tablets | — | 0/31 (0%) | 6/31 (19.4%) |
| Lina+Met FDC Tablet | — | 1/32 (3.1%) | 9/32 (28.1%) |
| Event | Lina+Met Single Tablets | Lina+Met FDC Tablet |
|---|---|---|
| Clavicle fractureInjury, poisoning and procedural complications | 0/31 | 1/32 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/31 | 1/32 |
| Event | Lina+Met Single Tablets | Lina+Met FDC Tablet |
|---|---|---|
| HeadacheNervous system disorders | 5/31 | 5/32 |
| NauseaGastrointestinal disorders | 2/31 | 2/32 |
| VomitingGastrointestinal disorders | 2/31 | 0/32 |
| NasopharyngitisInfections and infestations | 0/31 | 2/32 |
| DiarrhoeaGastrointestinal disorders | 1/31 | 2/32 |
| Age Continuous(years) | Overall Study |
|---|---|
| Mean | 38.8 ± 9.9 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 17 |
| Male | 15 |
The record gives a start of Apr 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Linagliptin · Metformin